The Tumor Fraction Estimated by Rapid On-Site Evaluation Is Useful for Assessing the Suitability of Biopsy Specimens for Multiplex Genetic Testing.

IF 1.6 4区医学 Q3 PATHOLOGY

Acta Cytologica Pub Date : 2024-01-01 Epub Date: 2024-07-24 DOI:10.1159/000540451

Toshitaka Uehara, Daisuke Kawashima, Naoya Kanatani, Erika Hiraguchi, Kento Yoshida, Yosuke Masumoto, Yusuke Kuboyama, Yuka Hiraki, Emi Inumaru, Yoshihiro Ohishi

{"title":"The Tumor Fraction Estimated by Rapid On-Site Evaluation Is Useful for Assessing the Suitability of Biopsy Specimens for Multiplex Genetic Testing.","authors":"Toshitaka Uehara, Daisuke Kawashima, Naoya Kanatani, Erika Hiraguchi, Kento Yoshida, Yosuke Masumoto, Yusuke Kuboyama, Yuka Hiraki, Emi Inumaru, Yoshihiro Ohishi","doi":"10.1159/000540451","DOIUrl":null,"url":null,"abstract":"Introduction: Multiplex genetic testing (MGT) has become the mainstream method for genetic mutation testing in the field of lung cancer treatment, but the suitability criteria for MGT biopsy specimens are stringent. Although rapid on-site evaluation (ROSE) is considered a useful method for obtaining the suitable biopsy specimens for MGT, no direct comparisons of ROSE and MGT are available. In this study, we first evaluated the accuracy of MGT and ROSE in our hospital. Then, we explored the potential utility of the cytological findings of ROSE for indicating the adequacy of biopsy specimens for MGT.Methods: These analyses were performed retrospectively using the data of 74 patients with lung cancer who underwent ROSE at our hospital in 2020-2022.Results: Regarding the accuracy of MGT, the success rate was 97.9% and the frequency of epidermal growth factor receptor mutation in adenocarcinoma cases was 34.6%. The results of ROSE were then compared with histological diagnoses. The sensitivity and positive predictive value were 95.9% and 100.0%, respectively. To analyze the utility of the ROSE results for determining the adequacy of biopsy specimens for MGT, we determined the tumor fraction in the ROSE preparations (ROSE-T%) and the tumor fraction (B-T%)/tumor cell number (B-TN) in the biopsy specimens. When the threshold of the ROSE-T% was set at 80%, there were statistically significant biases of the B-T% ≥20%/B-TN ≥300 cases between the ROSE-T% ≥80% and <80% groups.Conclusion: This is the first report to suggest the utility of ROSE-T% in assessing the suitability of biopsy specimens for MGT. This predictive ability may add further value to ROSE and help reduce the time required for diagnostic testing, and thereby the patient burden.","PeriodicalId":6959,"journal":{"name":"Acta Cytologica","volume":" ","pages":"442-449"},"PeriodicalIF":1.6000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Cytologica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000540451","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/24 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PATHOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Multiplex genetic testing (MGT) has become the mainstream method for genetic mutation testing in the field of lung cancer treatment, but the suitability criteria for MGT biopsy specimens are stringent. Although rapid on-site evaluation (ROSE) is considered a useful method for obtaining the suitable biopsy specimens for MGT, no direct comparisons of ROSE and MGT are available. In this study, we first evaluated the accuracy of MGT and ROSE in our hospital. Then, we explored the potential utility of the cytological findings of ROSE for indicating the adequacy of biopsy specimens for MGT.

Methods: These analyses were performed retrospectively using the data of 74 patients with lung cancer who underwent ROSE at our hospital in 2020-2022.

Results: Regarding the accuracy of MGT, the success rate was 97.9% and the frequency of epidermal growth factor receptor mutation in adenocarcinoma cases was 34.6%. The results of ROSE were then compared with histological diagnoses. The sensitivity and positive predictive value were 95.9% and 100.0%, respectively. To analyze the utility of the ROSE results for determining the adequacy of biopsy specimens for MGT, we determined the tumor fraction in the ROSE preparations (ROSE-T%) and the tumor fraction (B-T%)/tumor cell number (B-TN) in the biopsy specimens. When the threshold of the ROSE-T% was set at 80%, there were statistically significant biases of the B-T% ≥20%/B-TN ≥300 cases between the ROSE-T% ≥80% and <80% groups.

Conclusion: This is the first report to suggest the utility of ROSE-T% in assessing the suitability of biopsy specimens for MGT. This predictive ability may add further value to ROSE and help reduce the time required for diagnostic testing, and thereby the patient burden.

查看原文本刊更多论文

通过现场快速评估估算出的肿瘤比例可用于评估活检样本是否适合进行多重基因检测。

简介：多重基因检测（MGT）已成为肺癌治疗领域基因突变检测的主流方法：多重基因检测（MGT）已成为肺癌治疗领域基因突变检测的主流方法，但 MGT 活检标本的适用性标准非常严格。虽然快速现场评估（ROSE）被认为是获取适合 MGT 的活检标本的有效方法，但目前还没有 ROSE 和 MGT 的直接比较。在本研究中，我们首先评估了本医院 MGT 和 ROSE 的准确性。然后，我们探讨了 ROSE 的细胞学结果在显示活检标本是否足以用于 MGT 方面的潜在作用：这些分析是利用 2020-2022 年在我院接受 ROSE 的 74 例肺癌患者的数据进行的回顾性分析：在MGT的准确性方面，成功率为97.9%，腺癌病例中表皮生长因子受体（EGFR）突变的频率为34.6%。然后将 ROSE 结果与组织学诊断结果进行比较。灵敏度和阳性预测值（PPV）分别为 95.9% 和 100.0%。为了分析 ROSE 结果在确定活检标本是否足以进行 MGT 的实用性，我们测定了 ROSE 制剂中的肿瘤比例（ROSE T%）和活检标本中的肿瘤比例（B-T%）/肿瘤细胞数（B-TN）。当 ROSE T% 的阈值设定为 80% 时，在 ROSE T% ≧80% 组和 <80%组之间，B-T% ≧20%/B-TN ≧300 例存在统计学上的显著偏差：这是第一份表明 ROSE T% 在评估活检标本是否适合用于 MGT 的报告。这种预测能力可能会进一步提高 ROSE 的价值，有助于缩短诊断检测所需的时间，从而减轻患者的负担。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta Cytologica 生物-病理学

CiteScore

3.70

自引率

11.10%

发文量

审稿时长

4-8 weeks

期刊介绍： With articles offering an excellent balance between clinical cytology and cytopathology, ''Acta Cytologica'' fosters the understanding of the pathogenetic mechanisms behind cytomorphology and thus facilitates the translation of frontline research into clinical practice. As the official journal of the International Academy of Cytology and affiliated to over 50 national cytology societies around the world, ''Acta Cytologica'' evaluates new and existing diagnostic applications of scientific advances as well as their clinical correlations. Original papers, review articles, meta-analyses, novel insights from clinical practice, and letters to the editor cover topics from diagnostic cytopathology, gynecologic and non-gynecologic cytopathology to fine needle aspiration, molecular techniques and their diagnostic applications. As the perfect reference for practical use, ''Acta Cytologica'' addresses a multidisciplinary audience practicing clinical cytopathology, cell biology, oncology, interventional radiology, otorhinolaryngology, gastroenterology, urology, pulmonology and preventive medicine.